Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Identify factors to be considered when choosing initial drug therapy for patients with multiple myeloma that minimizes potential limitations in future treatment options.
Identify patient, disease, and drug factors to be considered when sequencing therapy for individual patients with multiple myeloma.
Identify common toxicities associated with antimyeloma therapies and list monitoring parameters for serious toxicities.
Identify reasons for nonadherence to oral myeloma therapies and appropriate strategies to address them.
*
1 (Low)2345 (High)
Hans Lee, MD
Tiffany Richards, PhD, ANP, AOCNP
*
*